North America Obesity Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

North America Obesity Treatment Market Size

• The North America Obesity Treatment Market was valued at USD   22.75 million in 2024 and is expected to reach USD 68.99 Million by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 14.9% primarily driven by the increasing prevalence of obesity.
• This growth is driven by factors such as innovations in anti-obesity medications, growth in bariatric and metabolic surgeries. In addition, integration of digital health solutions in obesity treatment.

North America Obesity Treatment Market Analysis

• •  Obesity is a chronic medical condition characterized by excessive fat accumulation, increasing the risk of severe health complications such as cardiovascular diseases, type 2 diabetes, hypertension, and certain cancers
• Treatment options range from lifestyle modifications, pharmacotherapy, and medical devices to bariatric surgery, aiming to achieve sustainable weight loss and improve overall health outcomes
• The Europe obesity treatment market is driven by the rising prevalence of obesity due to sedentary lifestyles, unhealthy dietary habits, and genetic predisposition. Pharmacological interventions, including GLP-1 receptor agonists and appetite suppressants, play a crucial role in weight management, alongside behavioral therapy and lifestyle changes. Bariatric surgeries, such as gastric bypass and sleeve gastrectomy, are also gaining traction as effective long-term solutions for severe obesity
• The increasing demand for minimally invasive procedures and innovative anti-obesity medications is further propelling market growth
• North America remains a dominant region in the Europe obesity treatment market, supported by well-established healthcare infrastructure, high obesity rates, and continuous research in weight management solutions

• For instance, the U.S. leads in the adoption of GLP-1 receptor agonists like semaglutide and liraglutide, along with advancements in non-invasive medical devices designed for weight loss

• With a growing emphasis on obesity management and preventive healthcare, the Europe market is witnessing significant investments in novel therapies, medical technologies, and patient-centric solutions, driving overall industry expansion

Report Scope and Obesity Treatment Market Segmentation  

Europe Obesity Treatment Market Trends.

“Rising Adoption of Digital and AI-Driven Weight Management Solutions”

•  A key trend in the Europe obesity treatment market is the increasing adoption of digital and AI-driven weight management solutions

•  These innovative technologies enhance obesity management by providing personalized treatment plans, real-time monitoring, and data-driven insights to optimize weight loss strategies

• For instance, AI-powered mobile applications and wearable devices track physical activity, caloric intake, and metabolic rates, offering tailored recommendations to improve adherence and outcomes

•  Telemedicine platforms and virtual coaching further support patients by providing remote consultations, behavioral counseling, and medication management, leading to more effective and sustainable weight loss

•  This trend is revolutionizing obesity care by improving patient engagement, enhancing long-term treatment success, and driving demand for digital health solutions in the obesity treatment market

Europe Obesity Treatment Market Dynamics

Driver

Increasing Prevalence of Obesity”

• The obesity epidemic is escalating due to sedentary lifestyles, poor dietary habits, and genetic predisposition, leading to a sharp increase in obesity-related health complications such as diabetes, cardiovascular diseases, and hypertension
• Urbanization and technological advancements have contributed to reduced physical activity, while widespread consumption of processed and high-calorie foods has further fueled weight gain
• Genetic factors also play a significant role, with many individuals being predisposed to metabolic disorders that contribute to obesity. As obesity rates continue to surge, the demand for effective treatment solutions, including pharmacological therapies, bariatric surgeries, and medically supervised weight management programs, is rising significantly

For instance,

• In March 2024, as per the information provided by WHO, the Europe obesity epidemic is escalating, with 1 in 8 people living with obesity in 2022. Adult obesity has doubled since 1990, and adolescent obesity has quadrupled. Over 2.5 billion adults were overweight, including 890 million with obesity. Rising obesity rates contribute to increased risks of diabetes, heart disease, and cancer, fueling demand for effective treatments and driving market growth
• In September 2024, as highlighted by the Centers for Disease Control and Prevention, between August 2021 and August 2023, 40.3% of adults were living with obesity, with 39.2% of men and 41.3% of women affected. The highest prevalence was among adults aged 40–59 (46.4%), followed by 20–39 (35.5%) and 60+ (38.9%). The increasing obesity burden is expected to drive demand for effective obesity treatments

• In 2024, as mentioned by World Obesity Atlas, by 2035, 79% of overweight and obese adults and 88% of overweight and obese children will reside in Low- and Middle-Income Countries (LMICs). The number of adults with obesity is projected to increase from 0.81 billion in 2020 to 1.53 billion in 2035. This rising prevalence is increasing the demand for obesity treatment solutions, driving market growth

• This growing patient burden is driving healthcare providers, pharmaceutical companies, and wellness programs to expand their offerings, making the rising prevalence of obesity a key driver for the Europe obesity treatment market

Opportunity

“Increasing Prevalence of Lifestyle Related Diseases”

• As more individuals seek to manage their weight and mitigate associated health risks, pharmaceutical companies and healthcare providers are incentivized to innovate and expand their offerings
• This trend fosters the development of new medications, surgical options, and comprehensive lifestyle programs tailored to diverse patient needs

For instance,

• In May 2023, NCBI stated that it is estimated that more than 1 billion people will be living with obesity by 2030.1 The higher rates of obesity-associated mortality and comorbidities, such as diabetes, cardiovascular disease, chronic kidney disease, and several types of cancer, are equally staggering, with an average of 5 million deaths and 160 million disability-adjusted life-years
• In June 2023, according to an article published by Acta Pharmaceutica Sinica B, obesity strongly contributes to the development of cancer, cardiovascular diseases, type 2 diabetes, liver diseases and other disorders
• In April 2021, according to an article published in the American Heart Association Journals, Obesity contributes directly to incident cardiovascular risk factors, including dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. Obesity also leads to the development of cardiovascular disease and cardiovascular disease mortality independently of other cardiovascular risk factors
• In April 2023, a study by MoneyControl outlined that India has experienced a massive spike in lifestyle diseases, including an increase in the prevalence of early risk factors like obesity and cholesterol irregularities

• In addition, heightened awareness regarding the health consequences of obesity encourages proactive health management among consumers. With supportive initiatives from governments and health organizations promoting healthier lifestyles, the obesity treatment market is poised for substantial growth
• This momentum attracts investment and boosts research and development efforts, paving the way for a wide range of therapeutic interventions to meet the needs of an expanding patient population

Restraint/Challenge

“Long-Term Follow-Ups Associated With Obesity Treatment”

• Long-term follow-ups associated with obesity treatment primarily due to the complexity and resource intensiveness of such programs often requires continuous monitoring and support to ensure sustained weight loss and management, which can include regular consultations, nutritional guidance, and behavioral therapy
• These long-term commitments burden healthcare systems and pose logistical challenges for both patients and providers, leading to potential gaps in care and inconsistent treatment adherence

For instance,

• In December 2022, as per AJMC, managing obesity requires the ongoing partnership of a committed patient and informed clinicians. Managing obesity requires the ongoing partnership of a committed patient and informed clinicians
• In September 2022, JAMA Network reported that, in research carried for 175 patients, 94 (53.7%) had weight loss of at least 5% and 26 (14.9%) had weight loss of 10% or more at 3 months. Of 102 patients who were followed up for 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more
• In November 2021, according to an article published by the National Library of Medicine, ensuring a long-term follow-up seems to be of the utmost importance for bariatric patients. Low quality follow-up in bariatric surgery is indicated as a risk factor for poor outcomes but the versatility and effectiveness of follow-up are also determinants of clinical research

• Moreover, the necessity for long-term follow-ups deters individuals from seeking treatment initially. Many prospective patients may be apprehensive about the ongoing commitment and costs associated with regular check-ins and monitoring, which is perceived as daunting or inconvenient
• This hesitancy impedes market growth, as potential consumers shy away from programs that require sustained engagement and accountability
• Consequently, the challenge of facilitating effective long-term follow-ups may limit the overall effectiveness of obesity treatments and their acceptance among the target population

Europe Obesity Treatment Market Scope

The market is segmented on the basis of type, product type, absorption site, age group, source, delivery method, gender, and distribution channel.

Europe obesity treatment market Regional Analysis

“North America is the Dominant Region in the obesity treatment market ”

• North America leads the Europe obesity treatment market, driven by a high prevalence of obesity, advanced healthcare infrastructure, and strong adoption of innovative weight management solutions
• The U.S. holds a significant market share due to the rising demand for pharmacological treatments like GLP-1 receptor agonists, bariatric surgeries, and digital weight management platforms
• In addition, increasing awareness about obesity-related health risks and the growing adoption of AI-driven weight loss programs, telehealth consultations, and non-invasive treatment solutions continue to fuel market expansion in the region

“South America is Projected to Register the Highest Growth Rate”

• The South American region is expected to witness the highest growth rate in the Europe obesity treatment market, driven by increasing obesity prevalence, rising healthcare investments, and growing awareness about weight management solutions
• Countries such as Brazil, Argentina, and Chile are emerging as key markets due to shifting lifestyle patterns, rising urbanization, and an increasing number of obesity-related health complications
• Brazil, with its expanding healthcare infrastructure and growing demand for medical weight loss treatments, remains a crucial market for obesity management. The country is witnessing increased adoption of pharmacological treatments, bariatric surgeries, and digital weight management programs

Europe obesity treatment market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (U.S.)
• Medtronic (U.S.)
• Boston Scientific Corporation (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Altimmune (U.S.)
• AstraZeneca (U.K.)
• Allurion (U.S.)
• Amgen Inc. (U.S.)
• Arena Pharmaceuticals Ltd (U.S.)
• Currax pharmaceuticals LLC (U.S.)
• COUSIN SURGERY (France)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Fitterfly Healthtech Pvt. Ltd. (India)
• Morphic Medical, Inc (U.S.)
• Noom, Inc. (U.S.)
• Omada Health Inc (U.S.)
• Reshape Lifesciences Inc. (U.S.)
• Raziel (Isarel)
• Spatz FGIA Inc. (U.S.)
• Sanofi (France)
• Saniona (Denmark)
• USGI Medical (U.S.)
• VIVUS LLC. (U.S.)
• Viking Therapeutics (U.S.)

Latest Developments in Europe Obesity Treatment Market

• In October 2024, VIVUS and UpScriptHealth have launched ChooseQ. online, a telehealth platform that offers convenient access to QSYMIA for weight management. This service allows patients to consult with healthcare providers online and receive QSYMIA directly at home. This initiative aims to improve accessibility to obesity treatment through telemedicine
• In October 2024, Zealand Pharma announced that Boehringer Ingelheim received U.S. FDA Breakthrough Therapy designation for Survodutide (BI 456906) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced fibrosis. This designation accelerates its development due to promising Phase II results
• In March 2025, Zealand Pharma announced the completion of participant enrolment in the Phase 2b ZUPREME-1 trial for Petrelintide, a long-acting amylin analog aimed at treating overweight and obesity. The trial will assess the effects of various doses of Petrelintide on body weight, safety, and tolerability over 42 weeks, with results expected in 2025
• On March 2025, Raziel Therapeutics, a pharmaceutical company focused on next-generation prescription products for the medical aesthetics market, has announced the initiation of a Phase 3 clinical study in China for RZL-012, aimed at reducing submental fat (SMF). SMF reduction is the first indication for RZL-012, with potential applications for various aesthetic fat reduction treatments in body shaping
• In October 2022, ReShape Lifesciences, a leader in weight loss and metabolic health solutions, announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) have released updated guidelines for Metabolic and Bariatric Surgery, which now include the Lap-Band. These guidelines replace the previous 30-year-old standards established by the National Institutes of Health (NIH) in 1991

SKU-73843